Pegtibatinase + Placebo
Phase 1/2Active 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Homocystinuria
Conditions
Homocystinuria
Trial Timeline
Jan 22, 2019 → Dec 1, 2026
NCT ID
NCT03406611About Pegtibatinase + Placebo
Pegtibatinase + Placebo is a phase 1/2 stage product being developed by Travere Therapeutics for Homocystinuria. The current trial status is active. This product is registered under clinical trial identifier NCT03406611. Target conditions include Homocystinuria.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03406611 | Phase 1/2 | Active |
Competing Products
3 competing products in Homocystinuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SYNB1353 | Synlogic | Phase 1 | 25 |
| Pegtibatinase | Travere Therapeutics | Phase 3 | 72 |
| Pegtibatinase | Travere Therapeutics | Phase 3 | 72 |